A small clarification and a minor scope adjustment. v2 reorganizes and consolidates the instructions for the interim final rule in Section 2(a), making the requirements clearer. Additionally, v2 removes a provision that granted the Secretary of Health and Human Services discretion to make additional changes to the Code of Federal Regulations sections beyond the specified replacements.
FDA Modernization Act 3.0
- Sponsor
- Sen. Booker, Cory A. [D-NJ]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Dec 17, 2025
Bottom line
The bill streamlines FDA regulations to align with recent legislative changes that broaden the types of nonclinical testing methods acceptable for drug development, moving beyond exclusive reliance on animal testing.
What it actually does
This bill mandates the Secretary of Health and Human Services, through the FDA, to issue an interim final rule within one year. This rule will update various sections of Title 21 of the Code of Federal Regulations by replacing references to "animal" tests with "nonclinical" tests and incorporating the definition of "nonclinical test" from the Federal Food, Drug, and Cosmetic Act. It also includes a technical amendment to re-designate a subsection in the FD&C Act.
Proponents argue
Supporters argue this bill is crucial for modernizing drug development by ensuring FDA regulations reflect the latest scientific advancements in non-animal testing methods. They contend it will accelerate the development of new drugs, reduce the reliance on animal testing, and potentially lower costs for pharmaceutical companies, ultimately benefiting patients by bringing safe and effective treatments to market faster.
Opponents contend
Critics, if any, might express concerns about the potential for unintended consequences if the regulatory shift is not carefully managed, or if the new "nonclinical" methods are not as robust or predictive as traditional animal models for certain drug types. However, given the technical nature and alignment with existing law, widespread opposition is unlikely.
The bill is very short and clear, making it easily accessible for anyone to read and understand its core provisions within minutes.
Section 2(a)
Mandate for Interim Final Rule on Nonclinical Testing Methods
This provision requires the FDA to publish an interim final rule within one year. This rule will update existing regulations (specifically in Title 21 of the Code of Federal Regulations) to replace all mentions of "animal" tests, data, and research with the broader term "nonclinical" tests, data, and research. It also mandates adding the legal definition of "nonclinical test" to key regulatory sections, ensuring consistency with recent changes in federal law that allow for alternatives to animal testing in drug development.
Supporters argue
Supporters argue this provision is essential for implementing the intent of the Consolidated Appropriations Act, 2023, which expanded acceptable nonclinical testing methods beyond animal models. They contend it will accelerate drug development, reduce animal testing, and foster innovation by allowing the use of advanced scientific methods like organ-on-a-chip technology and computer modeling.
Critics contend
No specific opposition is typically raised against this provision, as it aligns with broader scientific and ethical trends towards reducing animal testing while maintaining drug safety and efficacy standards. Any potential concerns would likely revolve around the rigor of new nonclinical methods, but the bill merely codifies the allowance for these methods, not their mandatory use.
Tradeoffs
The primary tension is balancing the desire for faster, more ethical drug development with the need to ensure the safety and efficacy of new drugs, traditionally assessed through animal models. This provision aims to resolve this by formally recognizing validated non-animal methods as equally acceptable.
Section 2(b)
Technical Amendment for Subsection Redesignation
This provision makes a technical correction to the Federal Food, Drug, and Cosmetic Act. It re-labels a subsection concerning clinical trial diversity action plans from "subsection (z)" to "subsection (aa)". This is necessary because another recent law also added a subsection (z), creating a duplication. This amendment resolves the numbering conflict, ensuring clarity and proper referencing within the statute.
This subsection states that the interim final rule issued by the Secretary of Health and Human Services under paragraph (1) shall become immediately effective without requiring the Secretary to demonstrate good cause.
Section 2(a)(3)
Why it matters:While standard for some urgent regulatory actions, waiving the "good cause" requirement for immediate effectiveness can be seen as a way to expedite implementation without full public notice and comment periods typically required by the Administrative Procedure Act. In this context, it ensures rapid alignment with existing law.
Case for: Proponents argue that immediate effectiveness is necessary to quickly align FDA regulations with the already enacted statutory changes (Consolidated Appropriations Act, 2023). This prevents a lag where the law allows nonclinical testing but regulations still implicitly favor animal testing, thus accelerating modernization and reducing regulatory uncertainty for industry.
Case against: Critics of such provisions generally argue that bypassing the "good cause" requirement for immediate effectiveness can limit public input and transparency in the rulemaking process, potentially leading to less robust or less considered regulations. However, in this specific case, the rule is mandated to align with existing law, reducing the scope for novel policy decisions.
Estimated impact: This provision primarily impacts the timeline for regulatory implementation, accelerating the shift to nonclinical testing methods.